## Food and Drug Administration, HHS

- (vii) In vitro diagnostic products as defined in §809.3(a) of this chapter.
- (e) Manufacture means, but is not limited to, any or all steps in the recovery, processing, storage, labeling, packaging, or distribution of any human cell or tissue, and the screening or testing of the cell or tissue donor.
  - (f) Minimal manipulation means:
- (1) For structural tissue, processing that does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement; and
- (2) For cells or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells or tissues.
- (g) *Transfer* means the placement of human reproductive cells or tissues into a human recipient.

EFFECTIVE DATE NOTE: At 66 FR 5466, Jan. 19, 2001, part 1271 was added, effective Apr. 4, 2001, except for \$1271.3(d)(2), which is effective Jan. 21, 2003.

## § 1271.10 Are my HCT/P's regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do?

- (a) An HCT/P is regulated solely under section 361 of the PHS Act and the regulations in this part if it meets all of the following criteria:
- (1) The HCT/P is minimally manipulated;
- (2) The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;
- (3) The manufacture of the HCT/P does not involve the combination of the cell or tissue component with a drug or a device, except for a sterilizing, preserving, or storage agent, if the addition of the agent does not raise new clinical safety concerns with respect to the HCT/P; and
  - (4) Either:
- (i) The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
- (ii) The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and:
  - (a) Is for autologous use;

- (b) Is for allogeneic use in a first-degree or second-degree blood relative; or
  - (c) Is for reproductive use.
- (b) If you are a domestic or foreign establishment that manufactures an HCT/P described in paragraph (a) of this section:
  - (1) You must register with FDA;
- (2) You must submit to FDA a list of each HCT/P manufactured; and
- (3) You must comply with the other requirements contained in this part.

## § 1271.15 Are there any exceptions from the requirements of this part?

- (a) You are not required to comply with the requirements of this part if you are an establishment that uses HCT/P's solely for nonclinical scientific or educational purposes.
- (b) You are not required to comply with the requirements of this part if you are an establishment that removes HCT/P's from an individual and implants such HCT/P's into the same individual during the same surgical procedure
- (c) You are not required to comply with the requirements of this part if you are a carrier who accepts, receives, carries, or delivers HCT/P's in the usual course of business as a carrier.
- (d) You are not required to comply with the requirements of this part if you are an establishment that does not recover, screen, test, process, label, package, or distribute, but only receives or stores HCT/P's solely for implantation, transplantation, infusion, or transfer within your facility.
- (e) You are not required to comply with the requirements of this part if you are an establishment that only recovers reproductive cells or tissue and immediately transfers them into a sexually intimate partner of the cell or tissue donor.
- (f) You are not required to register or list your HCT/P's independently, but you must comply with all other applicable requirements in this part, if you are an individual under contract, agreement, or other arrangement with a registered establishment and engaged solely in recovering cells or tissues and sending the recovered cells or tissues to the registered establishment.